SP7

Across TCGA pan-cancer cohorts, SP7 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SP7 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SP7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SP7 expression acts as an unfavorable survival marker.

LIHC, UCEC, and LUAD are the cancer types where SP7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.143	0.779	<.001	15	view →
UCEC	OS	Median	IV	0.066	0.755	<.001	12	view →
LUAD	OS	Median	All	0.250	0.788	.010	9	view →
LGG	OS	Median	All	0.332	0.830	.009	6	view →
CESC	DFS	Median	All	0.107	0.544	.049	6	view →
READ	OS	Median	All	0.281	0.830	.006	3	view →
BLCA	OS	Median	IV	0.141	0.573	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SP7–LIHC (OS)

Open the LIHC breakdown →